Gnosis by Lesaffre has acquired NattoPharma, a Norwegian nutraceutical company that specialises in the research and supply of vitamin K2.
The acquisition will see Gnosis by Lesaffre enhance its vitamin K2 offering by bringing together its own vitaMK7 brand with NattoPharma’s MenaQ7 solutions. Both ingredient solutions have been used as part of formulations for nutraceutical and functional food products for over ten years.
As part of the deal, the companies aim to expand the awareness and benefits of vitamin K2 for optimal bone and cardiovascular health; as well as expand their capabilities as suppliers of vitamin K2 through further global reach and future innovations.
“From our joints to our arteries all the way down to our cells, vitamin K2 is essential for the function of several calcium-binding proteins that empower us to thrive as human beings,” said Marc Philouze, Gnosis by Lesaffre general manager.
“We’re proud to help satiate the global demand for this key ingredient by joining efforts with NattoPharma.”
NattoPharma CEO, Kjetil Ramsoy, said: “I am proud of the entrepreneurial journey accomplished by the NattoPharma team to build the vitamin K2 market and supporting science over the past decade.
“Lesaffre is recognised as a worldwide key player in the fermentation industry, leveraging innovation and industrial platforms to produce fermentation products. This, paired with NattoPharma’s expertise on the various forms of vitamin K2, makes us confident that together we will accelerate research and further explore K2 benefits as the true global leader in vitamin K2 with a full range of products meeting all customer needs.”
Following the transaction – which was made for an undisclosed sum – NattoPharma joins the Lesaffre Group. Gnosis by Lesaffre was formed in 2018 following the acquisition of Italian biotechnology company by Lesaffre.
© FoodBev Media Ltd 2024
